Independent educationNo sales. No dosing. Sources on every brief.
The Peptide Field
Menu

Topic desk · 3 reviewed briefs

Recovery and repair claims

Track the leap from cells and animals to claims about tendon, muscle, wound, and post-injury recovery in people.

Evidence boundary

Biological plausibility is not a clinical repair outcome. Fragment identity, route, sterility, and impurity risks remain part of the evidence.

Reviewed briefs
3
Established contexts
0
Reviewed claims
9

Before accepting a claim

Ask the question the promotion leaves out.

  1. 01

    Is the finding from cells, animals, human pharmacology, or a controlled outcome trial?

  2. 02

    Is the marketed molecule identical to the one in the source?

  3. 03

    Does the claim ignore product-quality and anti-doping boundaries?

Connected briefs

Compare evidence without flattening it.

Open full evidence matrix ↗
Investigational human outcomesEmerging for reviewed context

BPC-157

An investigational peptide with a sizable preclinical literature, early human work, and a large gap between biological signal and proven clinical effect.

3 reviewed claims · Open brief ↗
Preclinical or formulation evidenceInsufficient for reviewed context

TB-500

A seven-amino-acid thymosin fragment promoted for repair despite an unresolved human-outcome gap, significant product questions, and anti-doping prohibition.

3 reviewed claims · Open brief ↗
Preclinical or formulation evidenceEmerging for reviewed context

GHK-Cu

A copper-binding tripeptide with topical and laboratory research that does not validate injectable, whole-body, or longevity claims.

3 reviewed claims · Open brief ↗